Next-gen drugs can help power growth and income alike.
The revenue in question seems too small to make a difference.
The stock falls after investors get a peek at the royalty-rate structure that pharma giant Roche will pay if a promising new cancer drug is approved.
The pharma's earnings may not look great, but bailing out could prove costly for investors if its Alzheimer's drug is successful.
Shares dip on news that the FDA needs more review time.
With antibodies produced from mouse and human components, this biotech is advancing drug research.
Investors hope the company has a next-generation treatment for the virus. The new data will fuel more takeover talk.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
With the universe of this category in its seasonal sweet spot, these picks have tailwinds propelling them into the new year.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.